Table 1.
Baseline demographic and clinical characteristics
| Characteristic | Ixekizumab (n = 155) | Secukinumab (n = 158) | |
|---|---|---|---|
| Age [years] | 42.0 ±11.3 | 41.1 ±13.7 | |
| Male sex, n (%) | 117 (75.50) | 111 (70.25) | |
| Weight [kg] | 87.3 ±15.4 | 85.7 ±17.3 | |
| Duration of psoriasis [years] | 18.1 ±18.7 | 17.6 ±14.5 | |
| Body-surface area affected by psoriasis (%) | 27.3 ±13.2 | 27.1 ±15.1 | |
| PASI score | 17.6 ±8.4 | 16.9 ±7.7 | |
| PGA score, n (%): | |||
| 0–2 | 0 | 0 | |
| 3 | 71 (45.81) | 79 (50.00) | |
| 4 | 62 (40.00) | 68 (43.04) | |
| 5 | 13 (8.39) | 11 (6.96) | |
| DLQI score | 12.3 ±7.2 | 13.1 ±4.6 | |
| Previous psoriasis treatment: | |||
| Topical therapy | 155 (100.0) | 158 (100.0) | |
| Phototherapy | 87 (56.13) | 91 (57.60) | |
| Systemic non-biologic treatment | 64 (41.29) | 69 (43.67) | |
| Systemic biologic treatment | 28 (18.06) | 26 (16.46) | |